Rani Therapeutics Trades Slightly Higher Amidst Volatile Market Activity

Rani Therapeutics (RANI) experienced a modest uptick of 0.46 % during the 24‑hour trading window that concluded at 03:14 PM Central European Time on Wednesday, 21 March 2026. At the close, a single share was available on major exchanges for approximately USD 0.65.

The company’s share supply currently stands at 139.5 million, and its market capitalisation is USD 90.7 million. Over the past 24 hours, trading volume has amounted to roughly USD 298 thousand, reflecting a relatively low level of liquidity compared to larger peers.

Historical Performance

Rani Therapeutics has seen a notable decline of 17.24 % since the end of the previous month. The 200‑day simple moving average sits at USD 0.96, indicating that the current price is below its long‑term average. The stock’s peak over the last 52 weeks was USD 2.63, reached on 11 June 2025, while its 52‑week low was USD 0.61 on 13 July 2026.

Context within the S&P Health Care Index

In the same 24‑hour period, several comparable stocks displayed varied movements:

  • Team (TISI) climbed 3.88 %, trading at USD 24.10 with a market capitalisation of USD 106.3 million.
  • Dmc Global (BOOM) advanced 1.51 %, now at USD 5.37 and a market cap of USD 108.7 million.
  • Merlin (MRLN) fell 1.87 %, priced at USD 1.05 with a market value of USD 108.1 million.
  • Tevogen (TVGN) gained 0.74 %, trading at USD 6.82 and a market cap of USD 106.5 million.
  • LifeMD (LFMD) remained flat at USD 2.25, holding a market capitalisation of USD 108.5 million.

LifeMD announced the forthcoming release of its third‑quarter 2026 financial results on 9 November, ahead of the U.S. markets opening. A conference call will be held at 8:30 a.m. Eastern Time, offering investors an opportunity to discuss the results and address questions. The company’s platform integrates primary care, specialty services, and home‑delivery pharmacy, reinforcing its commitment to expanding access to affordable, high‑quality care across the United States.

Company Overview

Rani Therapeutics Holdings, Inc., headquartered in San Jose, California, operates as a holding company within the healthcare sector. Its subsidiaries focus on the development of orally administered biologics, aiming to transform medicine and enhance patient outcomes. Rani Therapeutics is listed on the Nasdaq stock exchange and maintains an online presence at www.ranitherapeutics.com .